Clinical Trials · NCT03987451
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 71
- Start date
- Jun 2019
- Locations
- 38 sites, 5 countries
- Primary endpoint
- Percentage of Participants With At Least One Stage of Liver Fibrosis Improvement With No Worsening of Non-Alcoholic Steatohepatitis (NASH) After 48 Weeks